Amneal Announces Solid Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amneal Pharmaceuticals (AMRX) Reports In-Line Q3 EPS, Revenues Miss
November 7, 2018 6:58 AM ESTAmneal Pharmaceuticals (NYSE: AMRX) reported Q3 EPS of $0.28, in-line with the analyst estimate of $0.28. Revenue for the quarter came in at $476.46 million versus the consensus estimate of $485.97 million.
"The third quarter was defined by solid financial performance and strategic accomplishments as we advanced the integration of Impax and Amneal, completed two strategic partnerships that strengthen our portfolio and launched 11 new generic products," said Rob Stewart, President and CEO of Amneal. "We delivered revenue of $476 million and adjusted... More
